Corresponding Application Previously Granted in the U.S. as the Company Continues to Create Global Barriers to Entry for its Novel Technology HINGHAM, Mass. , Nov. 03, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to aggressively protect its global intellectual property
Growing SAB Roster Includes 11 KOLs from Across the U.S. , Europe , and Israel Expansion of KOL Presence and Global Centers of Excellence Continues to Accelerate the Progression of the LIBERTY ® Robotic System to Meet Future Regulatory and Commercialization Milestones HINGHAM, Mass. , Oct.
HINGHAM, Mass. , Oct. 25, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering with a single institutional investor for the purchase and sale of 1,022,495 shares of the Company’s common stock (which
HINGHAM, Mass. , Oct. 21, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 1,022,495 shares of the Company’s common stock (which includes pre-funded
HINGHAM, Mass. , Oct. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it has submitted the anticipated follow-up pre-submission package for the LIBERTY ® Robotic System to ensure the Company remains fully aligned with the U.S.
HINGHAM, Mass. , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY® Robotic System, the first disposable robotic system being developed for endovascular procedures.
Suspending Development of SCS and Evaluating Alternatives for SCS Assets HINGHAM, Mass. , Oct. 11, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has announced that, following the recent acquisition of the endovascular assets of Nitiloop Ltd.
Complements Existing Allowance in the U.S. as Global Jurisdictions Recognize the Uniqueness of the Technology HINGHAM, Mass. , Oct. 10, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is continuing to expand its global intellectual property portfolio for the LIBERTY ® Robotic System
Integration with the LIBERTY® Robotic System & One & Done™ Technology May Enable Future Acceleration of Robotic Adoption; Represents an Additional Growth Opportunity by Accessing the $500 Million Chronic Total Occlusion (CTO) Market 1 through the Expansion of Robotic Ecosystem for Endovascular
